Evidence map›Paper›PMID 40229756›Full record

ArticleBMC cancer2025

Loss of chromosome Y is unrelated to the composition of the tumor microenvironment and patient prognosis in muscle-invasive urothelial bladder cancers.

Henning Plage, Viktoria Ahlburg, Sebastian Hofbauer, Kira Furlano, Sarah Weinberger, Annika Fendler, Florian Roßner, Simon Schallenberg, Sefer Elezkurtaj, Niclas C Blessin and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Henning PlageDepartment of Urology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Viktoria AhlburgInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Sebastian HofbauerDepartment of Urology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Kira FurlanoDepartment of Urology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Sarah WeinbergerDepartment of Urology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Annika FendlerDepartment of Urology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Florian RoßnerInstitute of Pathology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Simon SchallenbergInstitute of Pathology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Sefer ElezkurtajInstitute of Pathology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Niclas C BlessinInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Maximilian LennartzInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Andreas H MarxDepartment of Pathology, Academic Hospital Fuerth, Fuerth, Germany.
Henrik SamtlebenDepartment of Pathology, Academic Hospital Fuerth, Fuerth, Germany.
Margit FischDepartment of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Michael RinkDepartment of Urology, Marien Hospital Hamburg, Hamburg, Germany.
Marcin SlojewskiDepartment of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland.
Krystian KaczmarekDepartment of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland.
Thorsten EckeDepartment of Urology, Helios Hospital Bad Saarow, Bad Saarow, Germany.
Stefan KochDepartment of Pathology, Helios Hospital Bad Saarow, Bad Saarow, Germany.
Nico AdaminiDepartment of Urology, Albertinen Hospital, Hamburg, Germany.
Ronald SimonInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Guido SauterInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Henrik ZechaDepartment of Urology, Albertinen Hospital, Hamburg, Germany.
Joachim WeischenfeldtDepartment of Urology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Tobias KlatteDepartment of Urology, Helios Hospital Bad Saarow, Bad Saarow, Germany.
Sarah MinnerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
David HorstInstitute of Pathology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Thorsten SchlommDepartment of Urology, Charité - Universitätsmedizin , Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
Martina KluthInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany. m.kluth@uke.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLoss of chromosome Y (LOY) has recently been proposed to be associated with cancer aggressiveness, altered T-cell function, and poor prognosis in bladder carcinomas.

methodsChromosome Y was analyzed using fluorescence in-situ hybridization on a tissue microarray containing 2,071 urothelial carcinomas of the urinary bladder from male patients, including 487 patients who had undergone cystectomy for muscle-invasive disease and for whom follow-up data were available. Data on tumor microenvironment were obtained from a previous study.

resultsLOY was found in 26.0% of 1,704 analyzable cancers. In non-invasive cancers, LOY frequency was comparable in pTa G2 (22.8%) and pTa G3 (24.1%, p = 0.8036) carcinomas and slightly increased from pTa to pT2 - 4 carcinomas (23.1% for pTa and 27.2% for pT2 - 4) but these differences were not significant (p = 0.0794). In muscle-invasive cancers, LOY frequency slightly increased from pT2 (25.5%) to pT4 cancers (33.0%), but this association was not significant (p = 0.1814). Among pT2 - 4 cancers, LOY was associated with venous invasion (p = 0.0010) but unrelated to pT, pN, and L-status, as well as to overall, recurrence-free, and cancer-specific survival. Muscle-invasive urothelial carcinomas with and without LOY did not show significant differences in the number of CD8 positive lymphocytes, fraction of CD8 positive intraepithelial lymphocytes, number of macrophages and dendritic cells, and fraction of T helper and T regulatory cells.

conclusionThe lack of a clear association of LOY with histopathological parameters of cancer aggressiveness, patient prognosis, and parameters describing the tumor microenvironment strongly argues against the driving role of LOY in bladder cancer progression and cancer-associated immune reactions.

Indexed as

Chromosome DeletionChromosomes, Human, YTumor MicroenvironmentUrinary Bladder NeoplasmsAdultAgedAged, 80 and overFemaleHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedNeoplasm InvasivenessPrognosisLoss of chromosome YTissue microarrayTumor microenvironmentUrothelial bladder cancer

Identifiers

PMID40229756
PMCPMC11995540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.